blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2722051

EP2722051 - Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  13.09.2019
Database last updated on 11.09.2024
FormerThe patent has been granted
Status updated on  05.10.2018
FormerGrant of patent is intended
Status updated on  23.05.2018
FormerExamination is in progress
Status updated on  12.05.2017
Most recent event   Tooltip09.07.2021Lapse of the patent in a contracting state
New state(s): HU		published on 11.08.2021  [2021/32]
Applicant(s)For all designated states
Seattle Genetics, Inc.
21823 30th Drive, S.E.
Bothell, WA 98021 / US
[2014/17]
Inventor(s)01 / Doronina, Svetlana O.
10910 198th Place SE
Snohomish, WA 98296 / US
02 / Kline, Toni Beth
767 Bryant Street, No. 406
San Francisco, CA 94107 / US
 [2014/24]
Former [2014/17]01 / Doronina, Svetlana O.
10910 198th Place SE
Snohomish, Washington 98296 / US
02 / Kline, Toni Beth
2034B NW 60th Street
Seattle, Washington 981017 / US
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[N/P]
Former [2018/45]Andrews, Robert, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Former [2014/17]Andrews, Robert, et al
Mewburn Ellis LLP
33 Gutter Lane
London Greater London EC2V 8AS / GB
Application number, filing date13190752.907.07.2006
[2014/17]
Priority number, dateUS20050697767P07.07.2005         Original published format: US 697767 P
[2014/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2722051
Date:23.04.2014
Language:EN
[2014/17]
Type: B1 Patent specification 
No.:EP2722051
Date:07.11.2018
Language:EN
[2018/45]
Search report(s)(Supplementary) European search report - dispatched on:EP21.03.2014
ClassificationIPC:A61K38/00, C07K7/02
[2018/22]
CPC:
A61K47/65 (EP,US); C07K16/00 (US); A61K47/6811 (EP,US);
A61K47/6849 (EP,US); A61P1/00 (EP); A61P11/00 (EP);
A61P13/12 (EP); A61P17/00 (EP); A61P19/00 (EP);
A61P21/00 (EP); A61P25/00 (EP); A61P27/02 (EP);
A61P3/10 (EP); A61P31/00 (EP); A61P35/00 (EP);
A61P35/02 (EP); A61P37/00 (EP); A61P37/02 (EP);
A61P37/06 (EP); A61P37/08 (EP); A61P43/00 (EP);
A61P5/14 (EP); A61P7/00 (EP); A61P9/00 (EP);
A61P9/10 (EP); C07K16/2878 (EP,US); C07K5/0205 (EP,US);
C07K5/10 (US); C07K7/02 (EP,US); C07K7/06 (US);
A61K38/00 (EP,US); Y02A50/30 (EP,US) (-)
Former IPC [2014/17]A61K38/00, C07K7/02, A61K47/48
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2014/17]
TitleGerman:Monomethylvalinverbindungen mit Phenylalaninseitenkettenmodifikationen am C-Terminus[2014/17]
English:Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus[2014/17]
French:Composés de monométhylvaline présentant des modifications de la chaîne latérale de phénylalanine au niveau de la terminaison C[2014/17]
Examination procedure12.11.2013Examination requested  [2014/17]
13.02.2015Amendment by applicant (claims and/or description)
13.11.2015Despatch of a communication from the examining division (Time limit: M06)
17.06.2016Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
25.08.2016Reply to a communication from the examining division
03.05.2017Despatch of a communication from the examining division (Time limit: M04)
11.09.2017Reply to a communication from the examining division
24.05.2018Communication of intention to grant the patent
28.09.2018Fee for grant paid
28.09.2018Fee for publishing/printing paid
28.09.2018Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP06786489.2  / EP1917020
Divisional application(s)EP18200998.5  / EP3498289
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20060786489) is  25.10.2011
Opposition(s)08.08.2019No opposition filed within time limit [2019/42]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
25.08.2016Request for further processing filed
25.08.2016Full payment received (date of receipt of payment)
Request granted
05.09.2016Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
13.02.2015Request for further processing filed
13.02.2015Full payment received (date of receipt of payment)
Request granted
27.02.2015Decision despatched
Fees paidRenewal fee
12.11.2013Renewal fee patent year 03
12.11.2013Renewal fee patent year 04
12.11.2013Renewal fee patent year 05
12.11.2013Renewal fee patent year 06
12.11.2013Renewal fee patent year 07
12.11.2013Renewal fee patent year 08
28.07.2014Renewal fee patent year 09
27.07.2015Renewal fee patent year 10
27.07.2016Renewal fee patent year 11
27.07.2017Renewal fee patent year 12
27.07.2018Renewal fee patent year 13
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU07.07.2006
AT07.11.2018
CY07.11.2018
CZ07.11.2018
DK07.11.2018
EE07.11.2018
FI07.11.2018
LT07.11.2018
LV07.11.2018
MC07.11.2018
PL07.11.2018
RO07.11.2018
SE07.11.2018
SI07.11.2018
SK07.11.2018
TR07.11.2018
BG07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
LU07.07.2019
[2021/32]
Former [2021/26]AT07.11.2018
CY07.11.2018
CZ07.11.2018
DK07.11.2018
EE07.11.2018
FI07.11.2018
LT07.11.2018
LV07.11.2018
MC07.11.2018
PL07.11.2018
RO07.11.2018
SE07.11.2018
SI07.11.2018
SK07.11.2018
TR07.11.2018
BG07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
LU07.07.2019
Former [2020/27]AT07.11.2018
CZ07.11.2018
DK07.11.2018
EE07.11.2018
FI07.11.2018
LT07.11.2018
LV07.11.2018
MC07.11.2018
PL07.11.2018
RO07.11.2018
SE07.11.2018
SI07.11.2018
SK07.11.2018
TR07.11.2018
BG07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
LU07.07.2019
Former [2020/17]AT07.11.2018
CZ07.11.2018
DK07.11.2018
EE07.11.2018
FI07.11.2018
LT07.11.2018
LV07.11.2018
MC07.11.2018
PL07.11.2018
RO07.11.2018
SE07.11.2018
SI07.11.2018
SK07.11.2018
TR07.11.2018
BG07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
Former [2020/14]AT07.11.2018
CZ07.11.2018
DK07.11.2018
EE07.11.2018
FI07.11.2018
LT07.11.2018
LV07.11.2018
MC07.11.2018
PL07.11.2018
RO07.11.2018
SE07.11.2018
SI07.11.2018
SK07.11.2018
BG07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
Former [2019/50]AT07.11.2018
CZ07.11.2018
DK07.11.2018
EE07.11.2018
FI07.11.2018
LT07.11.2018
LV07.11.2018
PL07.11.2018
RO07.11.2018
SE07.11.2018
SI07.11.2018
SK07.11.2018
BG07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
Former [2019/40]AT07.11.2018
CZ07.11.2018
DK07.11.2018
EE07.11.2018
FI07.11.2018
LT07.11.2018
LV07.11.2018
PL07.11.2018
RO07.11.2018
SE07.11.2018
SK07.11.2018
BG07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
Former [2019/37]AT07.11.2018
CZ07.11.2018
DK07.11.2018
EE07.11.2018
FI07.11.2018
LT07.11.2018
LV07.11.2018
PL07.11.2018
RO07.11.2018
SE07.11.2018
BG07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
Former [2019/35]AT07.11.2018
CZ07.11.2018
DK07.11.2018
FI07.11.2018
LT07.11.2018
LV07.11.2018
PL07.11.2018
SE07.11.2018
BG07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
Former [2019/34]AT07.11.2018
DK07.11.2018
FI07.11.2018
LT07.11.2018
LV07.11.2018
SE07.11.2018
BG07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
Former [2019/26]AT07.11.2018
FI07.11.2018
LT07.11.2018
LV07.11.2018
SE07.11.2018
BG07.02.2019
GR08.02.2019
IS07.03.2019
PT07.03.2019
Former [2019/24]AT07.11.2018
FI07.11.2018
LT07.11.2018
LV07.11.2018
SE07.11.2018
BG07.02.2019
GR08.02.2019
IS07.03.2019
Former [2019/23]AT07.11.2018
FI07.11.2018
LT07.11.2018
LV07.11.2018
BG07.02.2019
IS07.03.2019
Former [2019/22]FI07.11.2018
LT07.11.2018
BG07.02.2019
IS07.03.2019
Former [2019/21]FI07.11.2018
LT07.11.2018
IS07.03.2019
Former [2019/20]LT07.11.2018
Documents cited:Search[XI]WO9413695  (BASF AG [DE]) [X] 1-4 * the whole document * * page 3; compound 70 * [I] 1-14;
 [I]US5767237  (SAKAKIBARA KYOICHI [JP], et al) [I] 1-14 * the whole document *;
 [XI]WO0118032  (BASF AG [DE], et al) [X] 1-4 * the whole document * [I] 1-14;
 [XI]WO2004010957  (SEATTLE GENETICS INC [US], et al) [X] 1-14 * the whole document * * pages 20-28 * [I] 1-14;
 [XI]WO2004073656  (SEATTLE GENETICS INC [US], et al) [X] 1-14 * the whole document * * pages 62-65 * [I] 1-14;
 [XI]WO2005001038  (SEATTLE GENETICS INC [US], et al) [X] 1-4 * the whole document * [I] 1-14;
 [XP]WO2005081711  (SEATTLE GENETICS INC [US], et al) [XP] 1-14 * the whole document *;
 [A]  - G Valle ET AL, "Constrained phenylalanine analogues. Preferred conformation of the 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) residue", International journal of peptide and protein research, DENMARK, (19920901), pages 222 - 232, URL: http://www.ncbi.nlm.nih.gov/pubmed/1335996, XP055105311 [A] 1-14 * the whole document *
 [A]  - MIYAZAKI ET AL, "Synthesis and antitumor activity of novel dolastatin 10 analogs", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, (19950101), vol. 43, no. 10, ISSN 0009-2363, pages 1706 - 1718, XP002080987 [A] 1-14 * the whole document * * page 1714; table 6; compounds 1,28b *
by applicantEP0012023
 EP0171496
 EP0173494
 WO8601533
 EP0184187
 WO8605807
 WO8702671
 US4694778
 WO8901036
 US4816567
 US4816397
 EP0404097
 US5047335
 US5122464
 WO9308829
 WO9311161
 US5225539
 US5229275
 WO9316185
 US5278299
 WO9404690
 US5500362
 US5510261
 US5545806
 US5545807
 US5565332
 US5567610
 US5569825
 US5571894
 US5573905
 US5583024
 US5585089
 US5587458
 US5589369
 US5591669
 US5625126
 US5633425
 US5635483
 US5641870
 US5661016
 US5663149
 WO9734631
 US5674713
 US5677171
 US5700670
 US5731168
 WO9813059
 US5739277
 US5780588
 US5821337
 US5888809
 US6214345
 WO02088172
 US6602677
 US2004006215
 WO2004073656
 US2006083736
    - KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 2264 - 2268
    - KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 5873 - 5877
    - ALTSCHUL ET AL., J. MOL. BIOL., (1990), vol. 215, pages 403 - 410
    - ALTSCHUL ET AL., NUCLEIC ACIDS RES., (1997), vol. 25, pages 3389 - 3402
    - TORELLIS; ROBOTTI, COMPUT. APPL. BIOSCI., (1994), vol. 10, pages 3 - 5
    - PEARSON; LIPMAN, PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 2444 - 8
    - HIGGINS ET AL., METHODS ENZYMOL., (1996), vol. 266, pages 383 - 402
    - RAVETCH; KINET, ANNU REV. IMMUNOL., (1991), vol. 9, pages 457 - 92
    - CLYNES ET AL., PROC. NATL. ACAD. SCI. USA, (1998), vol. 95, pages 652 - 656
    - DAËRON, ANNU. REV. IMMUNOL., (1997), vol. 15, pages 203 - 234
    - RAVETCH; KINET, ANNU. REV. IMMUNOL., (1991), vol. 9, pages 457 - 92
    - CAPEL ET AL., IMMUNOMETHODS, (1994), vol. 4, pages 25 - 34
    - DE HAAS ET AL., J. LAB. CLIN. MED., (1995), vol. 126, pages 330 - 41
    - GUYER, J. IMMUNOL., (1976), vol. 117, page 587
    - KIM ET AL., J. LMMUNOL., (1994), vol. 24, page 249
    - GAZZANO-SANTORO ET AL., J. IMMUNOL. METHODS, (1996), vol. 202, page 163
    - CHOTHIA; LESK, J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
    - PLÜCKTHUN, The Pharmacology of Monoclonal Antibodies, SPRINGER-VERLAG, (1994), vol. 113, pages 269 - 315
    - HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448
    - JONES, NATURE, (1986), vol. 321, pages 522 - 525
    - RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 329
    - PRESTA, CURR. OP. STRUCT. BIOL., (1992), vol. 2, pages 593 - 596
    - WILMAN, "Prodrugs in Cancer Chemotherapy", BIOCHEMICAL SOCIETY TRANSACTIONS, (1986), vol. 14, pages 375 - 382
    - "Prodrugs: A Chemical Approach to Targeted Drug Delivery", STELLA ET AL., Directed Drug Delivery, HUMANA PRESS, (1985), pages 247 - 267
    - The Chemistry of Heterocyclic Compounds, A series of Monographs, JOHN WILEY & SONS, (1950), vol. 13, 14,
    - J. AM. CHEM. SOC., (1960), vol. 82, page 5566
    - HAMBLETT, K.J. ET AL., Effect of drug loading on the pharmacology, pharmacokinetics, and toxicity of an anti-CD30 antibody-drug conjugate, AMERICAN ASSOCIATION FOR CANCER RESEARCH
    - HAMBLETT ET AL., CANCER RESEARCH, (2004), vol. 10, page 7063
    - 2004 ANNUAL MEETING, (20040327), vol. 45
    - ALLEY, S.C. ET AL., Controlling the Location of Drug Attachment in Antibody-Drug Conjugates, AMERICAN ASSOCIATION FOR CANCER RESEARCH
    - "2004 Annual Meeting", PROCEEDINGS OF THE AACR, (20040327), vol. 45
    - KANEKO, T. ET AL., BIOCONJUGATE CHEM, (1991), vol. 2, pages 133 - 41
    - TOKI ET AL., J ORG. CHERN., (2002), vol. 67, pages 1866 - 1872
    - HAY ET AL., BIOORG. MED. CHEM. LETT., (1999), vol. 9, page 2237
    - RODRIGUES ET AL., CHEMISTRY BIOLOGY, (1995), vol. 2, page 223
    - STORM ET AL., J. AMER. CHEM. SOC., (1972), vol. 94, page 5815
    - AMSBERRY ET AL., J. ORG. CHERN., (1990), vol. 55, page 5867
    - KINGSBURY ET AL., J. MED. CHEM., (1984), vol. 27, page 1447
    - WOYKE ET AL., ANTIMICROB. AGENTS AND CHEMOTHER., (2001), vol. 45, no. 12, pages 3580 - 3584
    - PETTIT ET AL., ANTIMICROB. AGENTS CHEMOTHER., (1998), vol. 42, pages 2961 - 2965
    - LAGUZZA ET AL., J. MED. CHEM., (1989), vol. 32, no. 3, pages 548 - 55
    - COLIGAN ET AL., Current Protocols in Protein Science, JOHN WILEY & SONS, (2002), vol. 2
    - TENG ET AL., PROC. NATL. ACAD. SCI. USA., (1983), vol. 80, pages 7308 - 7312
    - KOZBOR ET AL., IMMUNOLOGY TODAY, (1983), vol. 4, pages 72 - 79
    - OLSSON, METH. ENZYMOL., (1982), vol. 92, pages 3 - 16
    - KABAT E ET AL., J. IMMUNOLOGY, (1980), vol. 125, no. 3, pages 961 - 969
    - BERTER ET AL., SCIENCE, (1988), vol. 240, pages 1041 - 1043
    - LIU ET AL., PROC. NATL. ACAD. SCI. USA, (1987), vol. 84, pages 3439 - 3443
    - LIU ET AL., J. IMMUNOL., (1987), vol. 139, pages 3521 - 3526
    - SUN ET AL., PROC. NATL. ACAD. SCI. USA, (1987), vol. 84, pages 214 - 218
    - NISHIMURA ET AL., CANCER. RES., (1987), vol. 47, pages 999 - 1005
    - WOOD ET AL., NATURE, (1985), vol. 314, pages 446 - 449
    - SHAW ET AL., J. NATL. CANCER INST., (1988), vol. 80, pages 1553 - 1559
    - MORRISON, SCIENCE, (1985), vol. 229, pages 1202 - 1207
    - OI ET AL., BIOTECHNIQUES, (1986), vol. 4, page 214
    - JONES ET AL., NATURE, (1986), vol. 321, pages 552 - 525
    - VERHOEYAN ET AL., SCIENCE, (1988), vol. 239, page 1534
    - BEIDLER ET AL., J. IMMUNOL., (1988), vol. 141, pages 4053 - 4060
    - LONBERG; HUSZAR, INT. REV. IMMUNOL., (1995), vol. 13, pages 65 - 93
    - JESPERS ET AL., BIOTECHNOLOGY, (1994), vol. 12, pages 899 - 903
    - HOOGENBOOM; WINTER, J. MOL. BIOL., (1991), vol. 227, page 381
    - MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, page 581
    - "The rise of monoclonal antibodies as therapeutics", QUAN; CARTER, Anti-IgE and Allergic Disease, MARCEL DEKKER, (2002), pages 427 - 469
    - TRAIL ET AL., SCIENCE, (1993), vol. 261, pages 212 - 215
    - TRAIL ET AL., CANCER RESEARCH, (1997), vol. 57, pages 100 - 105
    - FRANCISCO ET AL., CANCER RES., (2000), vol. 60, pages 3225 - 3231
    - BOWEN ET AL., J. IM11LUNOL., (1993), vol. 151, pages 5896 - 5906
    - WAHL ET AL., CANCER RES., (2002), vol. 62, no. 13, pages 3736 - 42
    - FRANKE ET AL., CANCER BIOTHER. RADIOPHARM., (2000), vol. 15, pages 459 - 76
    - MURRAY, SEMIN ONCOL., (2000), vol. 27, pages 64 - 70
    - KUTMEIER ET AL., BIOTECHNIQUES, (1994), vol. 17, page 242
    - KOHLER; MILSTEIN, NATURE, (1975), vol. 256, pages 495 - 497
    - KOZBOR ET AL., IMMUNOLOGY TODAY, (1983), vol. 4, page 72
    - COLE ET AL., Monoclonal Antibodies and Cancer Therapy, ALAN R. LISS, INC., (1985), pages 77 - 96
    - HUSE ET AL., SCIENCE, (1989), vol. 246, pages 1275 - 1281
    - CLACKSON ET AL., NATURE, (1991), vol. 352, page 624
    - HANE ET AL., PROC. NATL. ACAD. SCI. USA, (1997), vol. 94, page 4937
    - HUTCHINSON ET AL., J. BIOL. CHEM., (1978), vol. 253, page 6551
    - MORRISON ET AL., PROC. NATL. ACAD. SCI., (1984), vol. 81, pages 851 - 855
    - NEUBERGER ET AL., NATURE, (1984), vol. 312, pages 604 - 608
    - TAKEDA ET AL., NATURE, (1985), vol. 314, pages 452 - 454
    - BIRD, SCIENCE, (1988), vol. 242, pages 423 - 42
    - HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 5879 - 5883
    - WARD ET AL., NATURE, (1989), vol. 334, pages 544 - 54
    - SKERRA ET AL., SCIENCE, (1988), vol. 242, pages 1038 - 1041
    - AUSUBEL, Molecular Cloning, A Laboratory Manual, 3rd ed.,, COLD SPRING HARBOR PUBLISH.
    - FOECKING ET AL., GENE, (1998), vol. 45, page 101
    - COCKETT ET AL., BIOTECHNOLOGY, (1990), vol. 8, page 2
    - RUTHER ET AL., EMBO J., (1983), vol. 2, page 1791
    - INOUYE; INOUYE, NUCLEIC ACIDS RES., (1985), vol. 13, pages 3101 - 3109
    - VAN HEEKE; SCHUSTER, J. BIOL. CHEM., (1989), vol. 24, pages 5503 - 5509
    - LOGAN; SHENK, PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, pages 355 - 359
    - BITTNER ET AL., METHODS IN ENZYMOL., (1987), vol. 153, pages 51 - 544
    - WIGLER ET AL., CELL, (1977), vol. 11, page 223
    - SZYBALSKA; SZYBALSKI, PROC. NATL. ACAD. SCI. USA, (1992), vol. 48, page 202
    - LOWY ET AL., CELL, (1980), vol. 22, page 817
    - WIGLER ET AL., PROC. NATL. ACAD. SCI. USA, (1980), vol. 77, page 357
    - O'HARE ET AL., PROC. NATL. ACAD. SCI. USA, (1981), vol. 78, page 1527
    - MULLIGAN; BERG, PROC. NATL. ACAD. SCI. USA, (1981), vol. 78, page 2072
    - CLINICAL PHARMACY, vol. 12, pages 488 - 505
    - WU; WU, BIOTHERAPY, (1991), vol. 3, pages 87 - 95
    - TOLSTOSHEV, ANN. REV. PHARMACOL. TOXICOL., (1993), vol. 32, pages 573 - 596
    - MULLIGAN, SCIENCE, (1993), vol. 260, pages 926 - 932
    - MORGAN; ANDERSON, ANN. REV. BIOCHEIN., (1993), vol. 62, pages 191 - 217
    - MAY, TIB TECH, (1993), vol. 11, no. 5, pages 155 - 215
    - SANTERRE ET AL., GENE, (1984), vol. 30, page 147
    - COLBERRE-GARAPIN ET AL., J. MOL. BIOL., (1981), vol. 150, page 1
    - BEBBINGTON; HENTSCHEL, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, ACADEMIC PRESS, (1987), vol. 3
    - CROUSE ET AL., MOL. CELL. BIOL., (1983), vol. 3, page 257
    - PROUDFOOT, NATURE, (1986), vol. 322, page 52
    - KOHLER, PROC. NATL. ACAD. SCI. USA, (1980), vol. 77, page 2197
    - KOHLER ET AL., NATURE, (1975), vol. 256, page 495
    - GODING, Monoclonal Antibodies: Principles and Practice, ACADEMIC PRESS, (1986), pages 59 - 103
    - KOZBOR, J. IMMUNOL., (1984), vol. 133, page 3001
    - BRODEUR ET AL., Monoclonal Antibody Production Techniques and Applications, MARCEL DEKKER, INC., (1987), pages 51 - 63
    - MUNSON ET AL., ANAL. BIOCHEM., (1980), vol. 107, page 220
    - SKERRA ET AL., CURR. OPINION IN IMMUNOL., (1993), vol. 5, pages 256 - 262
    - PLIICKTHUN, IMMUNOL. REVS., (1992), vol. 130, pages 151 - 188
    - MCCAFFERTY ET AL., NATURE, (1990), vol. 348, pages 552 - 554
    - CLACKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 628
    - MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, pages 581 - 597
    - MARKS ET AL., BIOLTECHNOLOGY, (1992), vol. 10, pages 779 - 783
    - WATERHOUSE ET AL., NUC. ACIDS. RES., (1993), vol. 21, pages 2265 - 2266
    - MORRISON, PROC. NATL ACAD. SCI. USA, (1984), vol. 81, page 6851
    - JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525
    - RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 327
    - VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, pages 1534 - 1536
    - SIMS ET AL., J. IMMUNOL., (1993), vol. 151, page 2296
    - CHOTHIA ET AL., J. MOL. BIOL., (1987), vol. 196, page 901
    - CARTER ET AL., PROC. NATL. ACAD. SCI. USA, (1992), vol. 89, page 4285
    - PRESTA ET AL., J. BNMUNOL., (1993), vol. 151, page 2623
    - JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, page 2551
    - JAKOBOVITS ET AL., NATURE, (1993), vol. 362, pages 255 - 258
    - BRUGGERMANN ET AL., YEAR IN BNMUNO., (1993), vol. 7, page 33
    - MCCAFFERTY ET AL., NATURE, (1990), vol. 348, pages 552 - 553
    - JOHNSON; CHISWELL, CURRENT OPINION IN STRUCTURAL BIOLOGY, (1993), vol. 3, pages 564 - 571
    - GRIFFITH ET AL., EMBO J., (1993), vol. 12, pages 725 - 734
    - MORIMOTO ET AL., JOURNAL OF BIOCHENZICAL AND BIOPHYSICAL METHODS, (1992), vol. 24, pages 107 - 117
    - BRENNAN ET AL., SCIENCE, (1985), vol. 229, page 81
    - CARTER ET AL., BIOLTECHNOLOGY, (1992), vol. 10, pages 163 - 167
    - MILLSTEIN ET AL., NATURE, (1983), vol. 305, pages 537 - 539
    - TRAUNECKER ET AL., EMBO J., (1991), vol. 10, pages 3655 - 3659
    - SURESH ET AL., METHODS IN ENZYMOLOGY, (1986), vol. 121, page 210
    - SHALABY ET AL., J. EXP. MED., (1992), vol. 175, pages 217 - 225
    - KOSTELNY ET AL., J. IRNNIUR2OL., (1992), vol. 148, no. 5, pages 1547 - 1553
    - GRUBER ET AL., J. IMMUNOL., (1994), vol. 152, page 5368
    - TUTT ET AL., J. 1MMUNOL., (1991), vol. 147, page 60
    - CUNNINGHAM; WELLS, SCIENCE, (1989), vol. 244, pages 1081 - 1085
    - CARON ET AL., J. EXP MED., (1992), vol. 176, pages 1191 - 1195
    - SHOPES, J. IMMUNOL., (1992), vol. 148, pages 2918 - 2922
    - WOLFF ET AL., CANCER RESEARCH, (1993), vol. 53, pages 2560 - 2565
    - STEVENSON ET AL., ANTI-CANCER DRUG DESIGN, (1989), vol. 3, pages 219 - 230
    - JEFFERIS; LUND, CHEM. IMMUNOL., (1997), vol. 65, pages 111 - 128
    - WRIGHT; MORRISON, TIBTECH, (1997), vol. 15, pages 26 - 32
    - BOYD ET AL., MOL. IMMUNOL., (1996), vol. 32, pages 1311 - 1318
    - WITTWE; HOWARD, BIOCHEM., (1990), vol. 29, pages 4175 - 4180
    - WYSS; WAGNER, CURRENT OPIFI. BIOTECH., (1996), vol. 7, pages 409 - 416
    - MALHOTRA ET AL., NATURE MED., (1995), vol. 1, pages 237 - 243
    - UMANA ET AL., NATURE BIOTECH., (1999), vol. 17, pages 176 - 180
    - HSE ET AL., J. BIOL. CHEM., (1997), vol. 272, pages 9062 - 9070
    - CROUCH ET AL., J. IMMUNOL. METH., (1993), vol. 160, pages 81 - 88
    - CREE ET AL., ANTICANCER DRUGS, (1995), vol. 6, pages 398 - 404
    - SCHRODER; LUBKE, The Peptides, ACADEMIC PRESS, (1965), vol. 1, pages 76 - 136
    - E. SCHRODER; K. LUBKE, The Peptides, ACADEMIC PRESS, (1965), vol. 1, pages 76 - 136
    - PETTIT ET AL., J. AM. CHEM. SOC., (1989), vol. 111, pages 5463 - 5465
    - PETTIT ET AL., ANTI-CANCER DRUG DESIGN, (1998), vol. 13, pages 243 - 277
    - PETTIT ET AL., J. CHEM. SOC. PERKIN TRANS., (1996), vol. 1, no. 5, pages 859 - 863
    - MIYAZAKI, CHEM. PHARM. BULL., (1995), vol. 43, no. 10, pages 1706 - 1718
    - BOWMAN ET AL., J. CHEM. SOC., (1950), pages 1342 - 1340
    - GREENE; WUTS, Protective Groups in Organic Synthesis, 2nd Edition,, JOHN WILEY & SONS, (1991), page 506
    - WALKER, J. ORG. CHEM., (1995), vol. 60, pages 5352 - 5
    - FRISCH ET AL., BIOCONJUGATE CHEM., (1996), vol. 7, pages 180 - 186
    - JONES ET AL., TETRAHEDRON LETTERS, (2000), vol. 41, no. 10, pages 1531 - 1533
    - GILON ET AL., TETRAHEDRON, (1967), vol. 23, no. 11, pages 4441 - 4447
    - ANGEW. CHEM., (1975), vol. 87, no. 14, page 517
    - DUBOWCHIK ET AL., TETRAHEDRON LETTERS, (1997), vol. 38, pages 5257 - 60
    - CROZET ET AL., TETRAHEDRON LETT., (1985), vol. 26, pages 5133 - 5134
    - SUN ET AL., BIOORGAITIC & MEDICINAL CHEMISTRY LETTERS, (2002), vol. 12, pages 2213 - 2215
    - SUN ET AL., BIOORGANIC & MEDICINAL CHEMISTRY, (2003), vol. 11, pages 1761 - 1768
    - KLUSSMAN ET AL., BIOCONJUGATE CHEMISTRY, (2004), vol. 15, no. 4, pages 765 - 773
    - GOODSON, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, (1984), vol. 2, pages 115 - 138
    - LANGER, SCIENCE, (1990), vol. 249, pages 1527 - 1533
    - AGNEW, CHEM IITTL. ED. ENGL., (1994), vol. 33, pages 183 - 186
    - WILLNER ET AL., BIOCONJUGATE CHEM., (1993), vol. 4, page 521
    - SYNTHESIS, (1982), vol. 245, page 881
    - KANEKO ET AL., BIOCONJUGATE CHEMISTRY, (1991), vol. 2, no. 3, pages 133 - 141
    - LAROCK, R.C., Comprehensive Organic Transformations, WILEY-VCH, (1999), page 1937
    - ZHOU ET AL., TETRAHEDRON: ASYMMETRY, (1999), vol. 10, no. 5, pages 855 - 862
    - TETRAHEDRON, (2002), vol. 9, no. 2, pages 217 - 229
    - JOURNAL OF ORGANIC CHEMISTRY, (2001), vol. 66, no. 4, pages 1339 - 1350
    - LAGO ET AL., JOURNAL OF ORGANIC CHEMISTRY, (1992), vol. 57, no. 12, pages 3493 - 6
    - RIGHI ET AL., TETRAHEDRON LETTERS, (1996), vol. 37, no. 38, pages 6893 - 6896
    - BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, (1982), vol. 55, no. 9, pages 3049 - 50
    - MATHUR ET AL., BIOPOLYMERS, (2004), vol. 76, no. 2, pages 150 - 161
    - JONSSON; MIKIVER, ACTA PHANNACEUTICA SUECICA, (1976), vol. 13, no. 1, pages 75 - 8
    - JOURNAL OF MEDICINAL CHEMISTRY, (1995), vol. 38, no. 10, pages 1600 - 7
    - TOTH ET AL., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, (2004), vol. 126, no. 34, pages 10538 - 10539
    - SCHLOSSER ET AL., TETRAHEDRON, (2004), vol. 60, no. 35, pages 7731 - 7742
    - ROFF ET AL., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, (2004), vol. 126, no. 13, pages 4098 - 4099
    - RUIZ ET AL., JOURNAL OF ORGANIC CHEMISTRY, (2003), vol. 68, no. 20, pages 7634 - 7645
    - WANG ET AL., TETRAHEDRON LETTERS, (2000), vol. 41, no. 9, pages 1307 - 1310
    - DAVIS ET AL., JOURNAL OF ORGANIC CHEMISTRY, (1999), vol. 64, no. 18, pages 6931 - 6934
    - EZQUERRA ET AL., JOURNAL OF ORGANIC CHEMISTRY, (1999), vol. 64, no. 18, pages 6554 - 6565
    - MENDOZA ET AL., "Promega Corp. Technical Bulletin TB288", CANCER RES., (2002), vol. 62, pages 5485 - 5488
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.